Reactions 890 - 23 Feb 2002 HRT increases the risk of breast cancer Recent, long term use of hormone replacement therapy (HRT) is associated with an increased risk of breast cancer, according to researchers from the US. Using data from the Group Health Cooperative (GHC) of Puget Sound, the researchers conducted a nested case-control study of 705 postmenopausal women (aged 50–74 years) who had been diagnosed with primary invasive breast cancer between 1 July 1990 and 31 December 1995, and 692 matched controls, to examine the association between HRT and breast cancer. Analysis of HRT use during the 5 years ending 1 year prior to diagnosis revealed that recent long-term use (≥ 57 months) of oral HRT * was associated with an increased risk of breast cancer compared with no HRT use during the 5-year period [odds ratio (OR)1.7; 95% CI 1.15–2.5]. The results were similar (60-85% increased risk) whether the women used estrogen alone or in combination with progestogen, and for both sequential and continuous therapy. Recent long-term use (≥ 57 months) of HRT was associated with a 3-fold increase in the risk of lobular cancer (OR 3.07; 95% CI 1.55–6.06) and a 50% increase in nonlobular (primarily ductal) cancer (OR 1.52; 95% CI 1.01–2.29). Current use of combination therapy was associated with a 4-fold increase in the risk of lobular breast cancer (3.91; 2.05–7.44). * measured as months of estrogen pill use with or without progestogen Chen C-L, et al. Hormone replacement therapy in relation to breast cancer. JAMA: the Journal of the American Medical Association 287: 734-741, 13 Feb 2002 800896446 1 Reactions 23 Feb 2002 No. 890 0114-9954/10/0890-0001/$14.95 Adis © 2010 Springer International Publishing AG. All rights reserved

HRT increases the risk of breast cancer

Download PDF Report

Upload
dinhliem
View
222
Download
3

Embed Size (px)

Citation preview

Reactions 890 - 23 Feb 2002

HRT increases the risk of breastcancer

Recent, long term use of hormone replacementtherapy (HRT) is associated with an increased risk ofbreast cancer, according to researchers from the US.

Using data from the Group Health Cooperative (GHC)of Puget Sound, the researchers conducted a nestedcase-control study of 705 postmenopausal women(aged 50–74 years) who had been diagnosed withprimary invasive breast cancer between 1 July 1990 and31 December 1995, and 692 matched controls, toexamine the association between HRT and breastcancer.

Analysis of HRT use during the 5 years ending 1 yearprior to diagnosis revealed that recent long-term use (≥57 months) of oral HRT* was associated with anincreased risk of breast cancer compared with no HRTuse during the 5-year period [odds ratio (OR)1.7; 95%CI 1.15–2.5]. The results were similar (60-85%increased risk) whether the women used estrogen aloneor in combination with progestogen, and for bothsequential and continuous therapy.

Recent long-term use (≥ 57 months) of HRT wasassociated with a 3-fold increase in the risk of lobularcancer (OR 3.07; 95% CI 1.55–6.06) and a 50% increasein nonlobular (primarily ductal) cancer (OR 1.52; 95% CI1.01–2.29). Current use of combination therapy wasassociated with a 4-fold increase in the risk of lobularbreast cancer (3.91; 2.05–7.44).* measured as months of estrogen pill use with or withoutprogestogen

Chen C-L, et al. Hormone replacement therapy in relation to breast cancer. JAMA:the Journal of the American Medical Association 287: 734-741, 13 Feb2002 800896446